← Leaderboards
Iain James Macleod
Aldatu Biosciences, Inc.
$14,130,476
Attributed
$14,130,476
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,130,476 · 6
By mechanism
R44$10,898,319 · 4
SB1$2,932,453 · 1
R43$299,704 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignSamplingDiagnosticPositioning AttributeTechnologyInnovationCountryEnsureSiteReproducibilityGenomicsValidationDrug ResistanceResistance MutationSpecificityDetectionPerformancePathogenLow And Middle-Income CountriesEvaluationGenotypeQuality ControlReagentPrototype
Grant awards (16)
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$975,023
R44 · FY2025 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$986,903
R44 · FY2024 · AI · contact PI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$957,844
SB1 · FY2024 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$943,229
R44 · FY2024 · AI · contact PI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$981,812
SB1 · FY2023 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$931,246
R44 · FY2023 · AI · contact PI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$992,797
SB1 · FY2022 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$964,499
R44 · FY2022 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$829,151
R44 · FY2022 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$865,501
R44 · FY2021 · AI · contact PI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$966,696
R44 · FY2019 · AI · contact PI
PANDAA for universal, pan-lineage molecular detection of Lassa fever infection$299,704
R43 · FY2019 · AI · contact PI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$973,600
R44 · FY2018 · AI · contact PI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$998,024
R44 · FY2017 · AI · contact PI
A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$691,049
R44 · FY2016 · AI · contact PI
A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$773,398
R44 · FY2015 · AI · contact PI